AZD4045
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
This modular study aims to evaluate the safety, tolerability, preliminary efficacy, and cellular kinetics of AZD4045 in participants with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose of AZD4045. Module 1 consists of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin.
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 101 patients (estimated)
- Sponsors
- AstraZeneca
- Tags
- CAR T Cell (Allogeneic), T Cell Engager (TCE), B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2276
- NCT Identifier
- NCT07681596
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.